Two Sigma Advisers
ATRA icon

Two Sigma Advisers’s Atara Biotherapeutics ATRA Stock Holding History

Two Sigma Advisers’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,692
Closed -$1.85M – 2731
2021
Q4 		$1.85M Sell
4,692
-13,084
-74% -$5.51M ﹤0.01% 1239
2021
Q3 		$7.96M Sell
17,776
-8,232
-32% -$2.95M 0.02% 586
2021
Q2 		$10.1M Sell
26,008
-6,272
-19% -$2.24M 0.03% 560
2021
Q1 		$11.6M Buy
32,280
+4,400
+16% +$1.94M 0.03% 518
2020
Q4 		$13.7M Buy
27,880
+12,208
+78% +$5.64M 0.04% 457
2020
Q3 		$5.08M Buy
15,672
+4,180
+36% +$1.42M 0.01% 760
2020
Q2 		$4.19M Buy
11,492
+1,456
+15% +$368K 0.01% 870
2020
Q1 		$2.13M Buy
10,036
+2,000
+25% +$635K 0.01% 1085
2019
Q4 		$3.31M Buy
8,036
+5,408
+206% +$1.86M 0.01% 1003
2019
Q3 		$928K Buy
+2,628
New +$981K ﹤0.01% 1476
2018
Q3 		– Sell
-392
Closed -$360K – 2227
2018
Q2 		$360K Buy
+392
New +$421K ﹤0.01% 2038

Other funds holding ATRA

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Two Sigma Advisers's ATRA Position: Q1 2022 in Review

Two Sigma Advisers sold out of Atara Biotherapeutics (ATRA) in Q1 2022, closing a stake of 4,692 shares — an estimated $1.85M sold.

Two Sigma Advisers first reported a position in ATRA in Q2 2018 and held it in 11 quarters. The position peaked at $13.7M in Q4 2020. 144 funds tracked by Wall St. Rank hold ATRA as of Q1 2022.

  • Two Sigma Advisers reported no remaining Atara Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 4,692 Atara Biotherapeutics shares in Q1 2022, an estimated $1.85M.
  • Two Sigma Advisers first reported a position in Atara Biotherapeutics in Q2 2018 and held it in 11 quarters.
  • Two Sigma Advisers's Atara Biotherapeutics position peaked at $13.7M in Q4 2020.
  • 144 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2022.

Based on Two Sigma Advisers's 13F filing for Q1 2022, filed 16 May 2022.